文献速递肾癌与肾肿瘤

转移性肾细胞癌一线治疗后的临床结局与不良事件:系统评价与网状Meta分析

Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · J Urol · 2021-09-21

该系统评价与网状Meta分析纳入4项III期随机对照试验(共3320例转移性肾细胞癌患者),比较免疫肿瘤联合方案一线治疗。N+C在总生存期排名第一,L+P在无进展生存期和客观缓解率排名第一,N+I在3级及以上不良事件最低方面排名第一。研究间随访时间、风险分组和肾切除术率存在差异。

要点

  • N+C可能提供最有利的总生存期,L+P可能提供最有利的无进展生存期和客观缓解率。
  • N+I在3级及以上不良事件最低方面排名第一。
  • 研究间随访时间、风险分组和肾切除术率差异可能影响结果普适性。

核心结论

  • N+C可能提供最有利的总生存期,L+P可能提供最有利的无进展生存期和客观缓解率,N+I毒性最低。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed数据库2016年1月1日至2021年3月6日,纳入4项III期随机对照试验(CheckMate 214、KEYNOTE-426、CheckMate 9ER、KEYNOTE-581),共3320例患者。

主要发现

  • 总生存期排名:N+C第一,其次L+P、P+A、N+I。
  • 无进展生存期和客观缓解率排名:L+P第一,其次N+C、P+A、N+I。
  • 3级及以上不良事件最低排名:N+I第一,其次P+A、N+C、L+P。

临床怎么用

  • 临床决策时可参考N+C在总生存期的优势、L+P在无进展生存期和客观缓解率的优势以及N+I的低毒性特征。

局限性

  • 研究间随访时间、风险分组和肾切除术率存在差异,可能影响结果的普适性和稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Four recent first-line clinical trials leveraging immune-oncology agents demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide formal comparisons among immune-oncology combinations in terms of OS, progression-free survival (PFS), objective response rates and treatment-related adverse events (AEs). MATERIALS AND METHODS: PubMed® database was searched for studies indexed from January 1, 2016 through March 6, 2021. Only phase III randomized clinical trials with proven OS benefit relative to sunitinib were included: CheckMate 214 (nivolumab plus ipilimumab [N+I]), KEYNOTE-426 (pembrolizumab plus axitinib [P+A]), CheckMate 9ER (nivolumab plus cabozantinib [N+C]) and KEYNOTE-581 (lenvatinib plus permbrolizumab [L+P]). OS represented the primary outcome. PFS, objective response rate and AEs represented secondary outcomes. RESULTS: Overall, 3,320 patients were included. Regarding OS, N+C ranked first, followed by L+P, P+A and N+I. Regarding PFS and objective response rate, L+P ranked first, followed by N+C, P+A and N+I. Finally, N+I ranked first with respect to lowest grade 3+ AEs, followed by P+A, N+C and L+P. Differences in followup duration, risk grouping and nephrectomy rates distinguish the studies. CONCLUSIONS: N+C may provide the most favorable OS, L+P the most favorable PFS and ORRs, and N+I the lowest toxicity. Population differences may potentially undermine the generalizability and the robustness of findings of metastatic renal cell carcinoma.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Nocera L, Karakiewicz PI, Wenzel M, et al. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. J Urol. 2021. PMID: 34546767. doi:10.1097/JU.0000000000002252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。